John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
1. Salpeter SR et al. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715-25.
2. Self T et al. Cardioselective beta-blockers in patients with asthma and concomitant heart failure or history of myocardial infarction: when do benefits outweigh risks? J Asthma. 2003;40:839-45.
3. Salpeter SR et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2005, issue 4, CD003566.
4. Salpeter SR et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Resp Med. 2003;97:1094-1101.
5. Farland MZ et al. Beta-blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47:651-6.
6. Chang CL et al. Cardioselective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193-200.
7. van der Woude HJ et al. Detrimental effects of beta-blockers in COPD. A concern for non-selective beta-blockers Chest. 2005;127:818-24.
8. Rutten FH et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-7.
9. Kotlyar E et al. Tolerability of carvedilol in patients with heart failure and chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290-5.